ASSESS ALL ALS Study

Официальное название

ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants

Обзор

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.

Первичные конечные точки

• ALS Functional Rating Scale-Revised (ALSFRS-R) [Срок оценки: Baseline, 4, 8, 12, 16, 20 and 24 months for ALS participants only.]
• ALS Functional Rating Scale-Revised Self entry (ALSFRS-RSE) [Срок оценки: Baseline, 2, 4 ,6, 8, 10, 12, 14,16, 18,20, 22 and 24 months for ALS participants only]

Вторичные конечные точки (7)

• ALS Impairment Multidomain scale (AIMS) [Срок оценки: 1, 3, 5,7,9,11,13,15,17,19,21 and 23 months from baseline for ALS participants only]
• Social Determinants of Health [Срок оценки: Months 3 and 4 for all cohorts]
• Environmental History [Срок оценки: Month 1 for all cohorts]
• Cognitive assessment (ECAS) [Срок оценки: Baseline, 12 and 24 months for all cohorts]
• Vital Capacity [Срок оценки: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants]
• Digital Speech Assessment [Срок оценки: Baseline, and monthly (at month 1,2, 3 through month 24 from baseline)]
• HHD of 3 hand muscles bilaterally [Срок оценки: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants]

Критерии участия

Inclusion Criteria for ALS participants:

• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• Diagnosis of ALS by a physician
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)

Inclusion Criteria for control participants:

• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)
• No history of familial ALS/Frontotemporal Dementia (FTD) in a close family member\*\* unless the participant has previously tested negative for the known causative ALS genes. Participants with a family history of singleton ALS are permitted to enroll.

• \*\* Defined by the presence of a known ALS causative gene such as C9orf72 in a family member or a family history suggestive of an inherited ALS/FTD syndrome defined by two family members with a history of ALS and/or FTD.
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)

Exclusion Criteria for all participants:

• Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression <= 90 days of screening, that would interfere with the study procedure, according to Investigator's judgement.
• Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment.

Exclusion Criteria for participants undergoing optional Lumbar Puncture

• Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
• Allergy to Lidocaine or other local anesthetic agents.
• Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
• Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
• Current pregnancy based on participant self-report
• Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

США · 36 центров

• University of Alabama Birmingham — Birmingham
• Barrow Neurological Institute — Phoenix
• University of California, Irvine — Irvine
• University of California San Diego — La Jolla
• University of California, Los Angeles — Los Angeles
• University of California, San Francisco — San Francisco
• University of Colorado Anschutz Medical Campus — Aurora
• Hospital For Special Care — New Britain
• … и ещё 28 центров

Пуэрто-Рико · 1 центр

• CHALS-CCT, University of Puerto Rico, Medical Sciences Campus — San Juan

Идентификаторы

NCT: NCT06578195 · 2024P001132 · 1OT2NS136938 · 1OT2NS136939

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗